Ad hoc:MorphoSys AG:Ad hoc correction: MorphoSys Announces Acquisition of Sloning

Thursday, 07. October 2010 17:02
MorphoSys AG /
/
Ad hoc correction: MorphoSys Announces Acquisition of Sloning
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.

This is a correction of the announcement from 15:28 07.10.2010 CEST. Reason for
the correction: The name of the acquired company was misstated in the last
sentence of the first paragraph and the first sentence of the second paragraph
of the announcement (refers only to the English version)

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the
acquisition of the private German company Sloning BioTechnology GmbH, a
biotechnology company developing new methods of synthetic biology. The
transaction will make MorphoSys the sole source of Sloning's state-of-the-art
Slonomics technology, which dramatically improves the assembly and quality of
protein libraries. By integrating Slonomics into its existing antibody
technology platform, MorphoSys expects to improve the generation of drug
candidates such that one in every two projects started reaches clinical
development. The technology will also be used to accelerate the generation of
both therapeutic and diagnostic antibodies. Sloning's shareholders received a
one-off EUR 19 million cash payment upon signing.

Sloning's financial results will be fully consolidated into MorphoSys's accounts
from today onwards, including significant tax loss carry-forwards. Today's
transaction is not material in respect of MorphoSys's financial guidance for
2010.



END OF AD HOC ANNOUNCEMENT



About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visithttp://www.morphosys.com/



HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys.



This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.




For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com





[HUG#1449952]



--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,Prime All Share,CDAX,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Ad hoc Announcement:
http://hugin.info/130295/R/1449952/391624.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE
Related Links: MorphoSys AG
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.